ATE496115T1 - Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutamin - Google Patents
Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutaminInfo
- Publication number
- ATE496115T1 ATE496115T1 AT04705562T AT04705562T ATE496115T1 AT E496115 T1 ATE496115 T1 AT E496115T1 AT 04705562 T AT04705562 T AT 04705562T AT 04705562 T AT04705562 T AT 04705562T AT E496115 T1 ATE496115 T1 AT E496115T1
- Authority
- AT
- Austria
- Prior art keywords
- colitis
- strains
- bifidobacterium
- days
- patients
- Prior art date
Links
- 241000186000 Bifidobacterium Species 0.000 title abstract 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title abstract 3
- 206010009887 colitis Diseases 0.000 abstract 5
- 229920003045 dextran sodium sulfate Polymers 0.000 abstract 3
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 abstract 2
- 241000700159 Rattus Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 206010070545 Bacterial translocation Diseases 0.000 abstract 1
- 208000037112 Intestinal Failure Diseases 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 241000186606 Lactobacillus gasseri Species 0.000 abstract 1
- 241000186605 Lactobacillus paracasei Species 0.000 abstract 1
- 241000700157 Rattus norvegicus Species 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000007375 bacterial translocation Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000009266 disease activity Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000002443 hepatoprotective effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000008383 multiple organ dysfunction Effects 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000005070 sampling Methods 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300245A SE526711C2 (sv) | 2003-01-31 | 2003-01-31 | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
| US44727403P | 2003-02-14 | 2003-02-14 | |
| PCT/SE2004/000098 WO2004067731A1 (en) | 2003-01-31 | 2004-01-27 | New strains of bifidobacterium having the ability to produce glutamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE496115T1 true ATE496115T1 (de) | 2011-02-15 |
Family
ID=20290264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04705562T ATE496115T1 (de) | 2003-01-31 | 2004-01-27 | Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutamin |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7947482B2 (enExample) |
| EP (1) | EP1587913B1 (enExample) |
| JP (1) | JP4540664B2 (enExample) |
| CN (1) | CN100558883C (enExample) |
| AT (1) | ATE496115T1 (enExample) |
| AU (1) | AU2004208084B2 (enExample) |
| BR (1) | BRPI0407176B8 (enExample) |
| CA (1) | CA2514659C (enExample) |
| DE (1) | DE602004031079D1 (enExample) |
| DK (1) | DK1587913T3 (enExample) |
| ES (1) | ES2362496T3 (enExample) |
| PL (1) | PL212096B1 (enExample) |
| RU (1) | RU2352628C2 (enExample) |
| SE (1) | SE526711C2 (enExample) |
| WO (1) | WO2004067731A1 (enExample) |
| ZA (1) | ZA200505777B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5363811B2 (ja) | 2005-09-28 | 2013-12-11 | ノルディスク リバランス アクティーゼルスカブ | 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療 |
| EP1951273B1 (en) * | 2005-10-06 | 2014-02-12 | Probi Ab | Use of lactobacillus for treatment of autoimmune diseases |
| WO2012005240A1 (ja) * | 2010-07-05 | 2012-01-12 | 株式会社明治 | 腸内腐敗物質の低減作用を有するビフィズス菌 |
| CL2010001124A1 (es) | 2010-10-14 | 2011-01-21 | Univ De Concepcion 50% Ma Loreto Ormeno 50% | Alimento funcional probiotico que comprende cepas viables de lactobacillus sp.; uso de dicho alimento funcional para contrarestar los efectos colaterales de la quimioterapia. |
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| CN103131647B (zh) * | 2011-11-29 | 2017-06-27 | 上海上药信谊药厂有限公司 | 婴儿双歧杆菌及其制剂 |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| CN108330166A (zh) * | 2017-09-06 | 2018-07-27 | 深圳市百澳飞生物技术有限公司 | 一种酶制剂的饲用活性评估方法 |
| CN113164526A (zh) | 2018-07-19 | 2021-07-23 | 潘德勒姆治疗公司 | 用于微生物植入的方法和组合物 |
| RU2699967C1 (ru) * | 2018-12-25 | 2019-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ комплексного лечения энтеральной недостаточности у детей с тяжелой термической травмой |
| US11045507B2 (en) | 2019-02-21 | 2021-06-29 | Ewelina Sosnowska-Turek | Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59155321A (ja) * | 1983-02-25 | 1984-09-04 | Riyoushiyoku Kenkyukai | 整腸用製剤 |
| DE3406772A1 (de) * | 1984-02-24 | 1986-03-13 | Angelo 8137 Berg Schuler | Diaetetisches mittel zur herabsetzung der harnstoffkonzentration in koerperfluessigkeiten und seine herstellung |
| SE9002732D0 (sv) * | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product containing growth factor |
| IT1254210B (it) | 1992-02-10 | 1995-09-14 | Simone Claudio De | Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego |
| JP3623977B2 (ja) * | 1993-10-29 | 2005-02-23 | 明治乳業株式会社 | 潰瘍性大腸炎治療剤 |
| JP4852681B2 (ja) * | 1996-02-28 | 2012-01-11 | 雪印メグミルク株式会社 | 腸管内細胞溶解活性抑制剤 |
| IT1288119B1 (it) * | 1996-06-28 | 1998-09-10 | Renata Maria Anna Ve Cavaliere | Composizioni dietetiche da utilizzare nell'alimentazione per via enterica |
| RU2112034C1 (ru) * | 1996-12-26 | 1998-05-27 | Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского | Штамм bifidobacterium infantis 73-15, используемый для приготовления бифидосодержащих бактерийных препаратов и продуктов лечебно-диетического питания |
| US6203797B1 (en) * | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| US6468525B1 (en) * | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
| CA2407724A1 (en) | 2000-05-03 | 2001-11-08 | University Of Maryland, Baltimore | Oral gram(+) bacteria and glutamine composition for prevention and/or treatment of gastro-intestinal |
| WO2002003879A1 (en) * | 2000-07-07 | 2002-01-17 | First Circle Medical, Inc. | Treatment of hiv using hyperthermia |
| JP2002186422A (ja) * | 2000-12-22 | 2002-07-02 | Morinaga Milk Ind Co Ltd | ラクトバシラス・ガッセリ及びビフィドバクテリウム属の菌を含有する非発酵食品 |
| FI109602B (fi) | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
| US7550285B2 (en) * | 2001-02-06 | 2009-06-23 | Nestec S.A. | Endotoxin binding lactic acid bacteria and bifidobacteria |
| US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
| US20030092163A1 (en) * | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| JP3364491B2 (ja) * | 2002-07-25 | 2003-01-08 | 株式会社アトリエ・ド・フロマージュ | ヨーグルトおよびその製造方法 |
-
2003
- 2003-01-31 SE SE0300245A patent/SE526711C2/sv not_active IP Right Cessation
-
2004
- 2004-01-27 CA CA2514659A patent/CA2514659C/en not_active Expired - Lifetime
- 2004-01-27 DE DE602004031079T patent/DE602004031079D1/de not_active Expired - Lifetime
- 2004-01-27 US US10/543,604 patent/US7947482B2/en active Active
- 2004-01-27 ZA ZA200505777A patent/ZA200505777B/en unknown
- 2004-01-27 EP EP04705562A patent/EP1587913B1/en not_active Expired - Lifetime
- 2004-01-27 CN CNB2004800088252A patent/CN100558883C/zh not_active Expired - Lifetime
- 2004-01-27 JP JP2006502776A patent/JP4540664B2/ja not_active Expired - Lifetime
- 2004-01-27 BR BRPI0407176A patent/BRPI0407176B8/pt not_active IP Right Cessation
- 2004-01-27 AU AU2004208084A patent/AU2004208084B2/en not_active Expired
- 2004-01-27 ES ES04705562T patent/ES2362496T3/es not_active Expired - Lifetime
- 2004-01-27 WO PCT/SE2004/000098 patent/WO2004067731A1/en not_active Ceased
- 2004-01-27 PL PL378435A patent/PL212096B1/pl unknown
- 2004-01-27 DK DK04705562.9T patent/DK1587913T3/da active
- 2004-01-27 AT AT04705562T patent/ATE496115T1/de not_active IP Right Cessation
- 2004-01-27 RU RU2005127331/13A patent/RU2352628C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| PL212096B1 (pl) | 2012-08-31 |
| AU2004208084A1 (en) | 2004-08-12 |
| RU2352628C2 (ru) | 2009-04-20 |
| BRPI0407176B8 (pt) | 2021-05-25 |
| CN100558883C (zh) | 2009-11-11 |
| SE0300245L (sv) | 2004-08-01 |
| SE526711C2 (sv) | 2005-10-25 |
| CN1777670A (zh) | 2006-05-24 |
| US20060269533A1 (en) | 2006-11-30 |
| ZA200505777B (en) | 2007-12-27 |
| DE602004031079D1 (de) | 2011-03-03 |
| CA2514659A1 (en) | 2004-08-12 |
| ES2362496T3 (es) | 2011-07-06 |
| SE0300245D0 (sv) | 2003-01-31 |
| RU2005127331A (ru) | 2006-01-27 |
| BRPI0407176B1 (pt) | 2018-05-08 |
| EP1587913A1 (en) | 2005-10-26 |
| DK1587913T3 (da) | 2011-04-11 |
| EP1587913B1 (en) | 2011-01-19 |
| US7947482B2 (en) | 2011-05-24 |
| PL378435A1 (pl) | 2006-04-03 |
| JP4540664B2 (ja) | 2010-09-08 |
| CA2514659C (en) | 2014-07-08 |
| BRPI0407176A (pt) | 2006-02-07 |
| JP2006516405A (ja) | 2006-07-06 |
| AU2004208084B2 (en) | 2008-10-09 |
| WO2004067731A1 (en) | 2004-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE496115T1 (de) | Neue bifidobacterium-stämme mit der fähigkeit zur herstellung von glutamin | |
| RU2465320C2 (ru) | Композиция штаммов рода lactobacillus для производства лекарственного средства | |
| CN108836956B (zh) | 甘草查耳酮a在制备治疗鸡坏死性肠炎药物中的用途 | |
| JPH07126177A (ja) | 潰瘍性大腸炎治療剤 | |
| CN1300617A (zh) | 一种补正气、泻邪气、调整人体阳气升降出入的中药组合物 | |
| CA3232874A1 (en) | Hygromycin a for treatment of diseases and infections | |
| Verdecia et al. | Trivalvular infective endocarditis secondary to Granulicatella adiacens and Peptostreptococcus spp | |
| Harboe | Armauer Hansen-the man and his work | |
| WO2019218986A1 (zh) | 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 | |
| CN105343132B (zh) | 治疗结肠炎的组合物、药物及其制备方法 | |
| MAKSUDOV et al. | Development of a comprehensive programme for the comprehensive treatment of patients with maxillofacial phlegmon with viral hepatitis B | |
| Ozcelik et al. | The role of lactulose in the prevention of bacterial translocation in surgical trauma | |
| JP2007522075A (ja) | 肝不全の治癒並びに肝臓代謝の再生及び強化のためのエンテロコッカス・フェシウム（ＥｎｔｅｒｏｃｏｃｃｕｓＦａｅｃｉｕｍ）菌株の使用 | |
| GB1585863A (en) | Pharmaceutical lactobacillus preparations | |
| Marshall Jr et al. | The variable effects of sulfonamides on fecal bacteria in patients with chronic ulcerative colitis: a preliminary report | |
| Wang et al. | Moxibustion at Front-Mu point of abdomen for intestinal dysbacteriosis in rats | |
| PAQUIN | ANTI-TUBERCLE SERUM. THE TREATMENT OF CONSUMPTION BY SEROTHERAPY—REPORT AND PRESENTATION OF CASES TREATED—EXHIBITION OF SERUM, ETC. | |
| Finley | Dermato-Myositis | |
| Crisostomo et al. | A randomized double blind controlled study on the efficacy of spirulina as an adjunct therapy in the management of pediatric community acquired pneumonia-c in patients 6 months to 5 years old admitted in a tertiary government hospital | |
| CN107073018A (zh) | 尿路感染的治疗 | |
| CN120249099A (zh) | 一株罗伊氏粘液乳杆菌ccfm1453制备的促进胃黏膜修复的多糖 | |
| CN120168459A (zh) | 独活素在制备治疗和/或缓解新生儿感染性疾病及脏器损伤的药物中的应用 | |
| RU2007103067A (ru) | Способ лечения хронических воспалительных заболеваний органов малого таза | |
| RU2008110773A (ru) | Способ лечения онкологических заболеваний | |
| Malsbary | Rheumatism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties | ||
| REN | Ceased due to non-payment of the annual fee |